daratumumab,talquetamab,teclistamab
genmab,janssen
['mmsm', 'tecli ', ' emd ']
#asco23 | response rates with tecli + talque are high, with 61% of patients still on treatment. the promising results in patients with emd (soft tissue plasmacytomas) have led to opening an expansion cohort for further evaluation in this subgroup #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma